Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 419-425

  Hu, M ^a   Mak, V W L ^a   Tomlinson, B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

diltiazem; drug interaction; genetic polymorphism; myopathy; rhabdomyolysis; simvastatin

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A5; DILTIAZEM; ENALAPRIL; MULTIDRUG RESISTANCE PROTEIN 1; NICERGOLINE; ORGANIC ANION TRANSPORTER 2; SIMVASTATIN;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; LABORATORY TEST; LIMB WEAKNESS; MULTIINFARCT DEMENTIA; MYOPATHY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; DILTIAZEM; DRUG INTERACTIONS; FEMALE; HONG KONG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; MUSCULAR DISEASES; POLYMORPHISM, GENETIC; SIMVASTATIN; TREATMENT OUTCOME;

EID: 79955750364     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01184.x     Document Type: Article

References (24)

1. Thompson PD, Clarkson P, Karas RH, (2003) Statin-associated myopathy. JAMA, 289, 1681-1690. (Pubitemid 37430274)
2. Rosenson RS, (2004) Current overview of statin-induced myopathy. American Journal of Medicine, 116, 408-416. (Pubitemid 38299486)
3. The SEARCH CollaborativeGroup (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. New England Journal of Medicine, 359, 789-799.
4. The Food and Drug Administration (2008) Information on simvastatin/amiodarone. Available at: (accessed 18, May 2010).
5. Mak YT, Pang CP, Tomlinson B, et al. (1998) Mutations in the low-density lipoprotein receptor gene in Chinese familial hypercholesterolemia patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 1600-1605. (Pubitemid 28465412)
6. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F, (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology and Therapeutics, 84, 413-428.
7. Holtzman CW, Wiggins BS, Spinler SA, (2006) Role of P-glycoprotein in statin drug interactions. Pharmacotherapy, 26, 1601-1607. (Pubitemid 44704473)
8. Mousa O, Brater DC, Sunblad KJ, Hall SD, (2000) The interaction of diltiazem with simvastatin. Clinical Pharmacology and Therapeutics, 67, 267-274. (Pubitemid 30176385)
9. Becquemont L, Neuvonen M, Verstuyft C, et al. (2007) Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clinical Pharmacology and Therapeutics, 81, 679-684. (Pubitemid 46625102)
10. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA, (1999) Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. American Journal of Cardiology, 84, 811-815. (Pubitemid 29469791)
11. Watanabe H, Kosuge K, Nishio S, et al. (2004) Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sciences, 76, 281-292. (Pubitemid 39456434)
12. You JHS, Chan WKY, Chung PFP, Hu M, Tomlinson B, (2010) Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects. Journal of Clinical Pharmacology. Available at: (accessed 18, May 2010).
13. Molden E, Skovlund E, Braathen P, (2008) Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Safety, 31, 587-596. (Pubitemid 351861951)
14. Ronaldson KJ, O'Shea JM, Boyd IW, (2006) Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Safety, 29, 1061-1067. (Pubitemid 44912714)
15. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM, (2001) Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tennesse Med, 94, 339-341.
16. Peces R, Pobes A, (2001) Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron, 89, 117-118. (Pubitemid 32799846)
17. Lewin JJ III, Nappi JM, Taylor MH, (2002) Rhabdomyolysis with concurrent atorvastatin and diltiazem. Annals of Pharmacotherapy, 36, 1546-1549.
18. Gladding P, Pilmore H, Edwards C, (2004) Potentially fatal interaction between diltiazem and statins. Annals of Internal Medicine, 140, W31.
19. Rifkin SI, (2008) Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report. Medscape Journal of Medicine, 10, 264.
20. DiGregorio RV, Pasikhova Y, (2009) Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy, 29, 352-356.
21. Hu M, Tomlinson B, (2009) Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction-what about the diltiazem? Pharmacotherapy, 29, 176e.
22. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B, (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovascular Drugs and Therapy, 19, 403-414. (Pubitemid 43228152)
23. Neuvonen PJ, Niemi M, Backman JT, (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics, 80, 565-581. (Pubitemid 44908269)
24. Tomlinson B, Hu M, Lee VWY, et al. (2010) ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clinical Pharmacology and Therapeutics. Available at: (accessed 18, May 2010).